Key result
Adjunctive SVCI fails to improve 12-month freedom from AF compared to PVI alone.
Why the study?
Non-pulmonary vein triggers, particularly the superior vena cava, may contribute to AF recurrence, but evidence on empirical SVC isolation using cryoballoon is limited and inconsistent.
Does adjunctive empirical superior vena cava isolation (SVCI) with a fourth-generation cryoballoon improve 12-month freedom from AF in patients with paroxysmal atrial fibrillation undergoing first-time PVI?
RCT (n=149)
Single-blind
Simple randomization (1:1 ratio)
No
Does adjunctive empirical superior vena cava isolation (SVCI) with a fourth-generation cryoballoon improve 12-month freedom from AF in patients with paroxysmal atrial fibrillation undergoing first-time PVI?
Hazard Ratio: 0.49 (95% CI 0.21–1.16)
Absolute Event Rate: 89.3% vs 79.7%
p-value: p=0.11
Adjunctive empirical superior vena cava isolation during initial cryoballoon ablation for paroxysmal AF does not significantly improve 1-year arrhythmia-free survival and is associated with increased procedural complications.
Adjunctive cryoballoon SVCI adds no AF freedom benefit yet increases complications; does not support routine use and challenges observational data.
Background Pulmonary vein isolation (PVI) is the cornerstone of atrial fibrillation (AF) ablation, but non-pulmonary vein triggers, particularly the superior vena cava (SVC), may contribute to recurrence. Cryoballoon (CB) ablation has been applied for empirical SVC isolation (SVCI), yet evidence is limited and inconsistent. Objective The CISPAF trial evaluated the feasibility, safety, and efficacy of adjunctive SVCI using a fourth-generation CB in patients undergoing first-time PVI for paroxysmal AF (PAF). Methods CISPAF was a prospective, randomized, single-centre trial including 149 patients with PAF assigned to PVI alone ( n = 74) or PVI + SVCI ( n = 75). Ablations were performed with a fourth-generation 28-mm CB. The primary endpoint was 12-month freedom from AF; safety endpoints included a composite of major procedure-related complications, with particular attention to phrenic nerve injury (PNI) and sinus node impairment. Results Acute PVI was achieved in all patients. SVCI succeeded in 62/75 (84.9%), with real-time isolation in 45 (60.0%). Major complications occurred only in the PVI + SVCI group (2.6% vs. 0%), including one sinus node injury requiring pacemaker implantation and one vascular complication requiring surgical repair. Transient or impending PNI and transient bradycardia/junctional rhythm were more frequent with PVI + SVCI (34.7% vs. 10.8% and 17.3% vs. 2.7%; respectively; both p < 0.01), but these events were self-limited and resolved after interruption of energy delivery. At 12 months, AF-free survival did not differ significantly between groups (89.3% vs. 79.7%; log-rank p = 0.096). Conclusion Adjunctive SVCI using a fourth-generation CB did not demonstrate a statistically significant improvement in arrhythmia-free survival at one year and was associated with a higher incidence of procedure-related complications. These findings do not support the routine use of empirical SVCI during initial CB ablation for PAF and should be interpreted as hypothesis-generating.
No takes yet. Share an insight, caveat, or question.
Pasara et al. (2026) conducted an RCT in Paroxysmal atrial fibrillation (n=149). Pulmonary vein isolation plus empirical superior vena cava isolation vs. Pulmonary vein isolation alone was evaluated on 12-month freedom from documented atrial fibrillation (HR 0.49, 95% CI 0.21-1.16, p=0.11). Adjunctive empirical superior vena cava isolation with a fourth-generation cryoballoon did not significantly improve 12-month freedom from atrial fibrillation compared to pulmonary vein isolation alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: